{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:24:11Z","timestamp":1778261051666,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["12\/IA\/1421"],"award-info":[{"award-number":["12\/IA\/1421"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-HEALTH-2011.1.4-4-280873"],"award-info":[{"award-number":["FP7-HEALTH-2011.1.4-4-280873"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.047","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T10:35:53Z","timestamp":1573468553000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4762-7607","authenticated-orcid":false,"given":"Craig P.","family":"McEntee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah B.T.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mu\u00f1oz-Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex M.","family":"Liddicoat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette","family":"Erbo-Wern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan S.","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3167-1080","authenticated-orcid":false,"given":"Ed C.","family":"Lavelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.047_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.047_b0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0255-0857(21)02834-6","article-title":"A pilot study of Chlamydia trachomatis pneumonia in infants","volume":"22","author":"Chawla","year":"2004","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/bjo.2008.148494","article-title":"Trachoma: global magnitude of a preventable cause of blindness","volume":"93","author":"Mariotti","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0020","article-title":"The global burden of trachoma: a review","volume":"3","author":"Burton","year":"2009","journal-title":"PLoS NeglTrop Dis"},{"key":"10.1016\/j.vaccine.2019.10.047_b0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/OLQ.0b013e3181d73e4c","article-title":"The direct cost of chlamydial infections: estimates for the employer-sponsored privately insured population in the United States, 2003\u20132007","volume":"37","author":"Owusu-Edusei","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2019.10.047_b0030","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1086\/315046","article-title":"The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection","volume":"180","author":"Su","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.047_b0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/aji.12008","article-title":"Transient detection of chlamydial-specific Th1 memory cells in the peripheral circulation of women with history of chlamydia trachomatis genital tract infection","volume":"68","author":"Vicetti Miguel","year":"2012","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0040","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3201\/eid2106.141270","article-title":"Cost-effectiveness of chlamydia vaccination programs for young women","volume":"21","author":"Owusu-Edusei","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.047_b0045","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/infdis\/jiv137","article-title":"Protection against chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein","volume":"212","author":"Olsen","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.047_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01652","article-title":"Protective effect of vaccine promoted neutralizing antibodies against the intracellular pathogen Chlamydia trachomatis","volume":"8","author":"Olsen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0055","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.4049\/jimmunol.1103032","article-title":"CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract","volume":"189","author":"Gondek","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0060","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/iai.65.3.1032-1044.1997","article-title":"Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin a response","volume":"65","author":"Johansson","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.047_b0065","first-page":"3331","article-title":"Modulation of transferrin synthesis, transferrin receptor expression, iNOS expression and NO production in mouse macrophages by cytokines, either alone or in combination","volume":"20","author":"Ryu","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2019.10.047_b0070","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1128\/iai.62.9.3705-3711.1994","article-title":"Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence","volume":"62","author":"Beatty","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.047_b0075","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.4049\/jimmunol.1001778","article-title":"Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-\u03b3 in a nitric oxide-dependent manner","volume":"185","author":"Fernandez-Boyanapalli","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1189\/jlb.0711336","article-title":"Chlamydia trachomatis vacuole maturation in infected macrophages","volume":"92","author":"Sun","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0085","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.143.11.3524","article-title":"Differential regulation of class II MHC determinants on macrophages by IFN-gamma and IL-4","volume":"143","author":"Cao","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4161\/auto.22482","article-title":"Autophagy restricts Chlamydia trachomatis growth in human macrophages via IFNG-inducible guanylate binding proteins","volume":"9","author":"Al-Zeer","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.vaccine.2019.10.047_b0095","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.4049\/jimmunol.0803458","article-title":"Autophagy and its role in MHC-mediated antigen presentation","volume":"182","author":"Crotzer","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0100","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.4049\/jimmunol.0901584","article-title":"IL-17\/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function","volume":"183","author":"Bai","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0105","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.10.047_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003116","article-title":"Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements","volume":"3","author":"Agger","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.047_b0115","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/mi.2016.70","article-title":"Subunit vaccine H56\/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung","volume":"10","author":"Woodworth","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00569","article-title":"Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted Chlamydia vaccine elicits elevated IgA and protective Th1\/Th17 responses in the genital tract","volume":"8","author":"Wern","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00380","article-title":"Heterologous prime-boost combinations highlight the crucial role of adjuvant in priming the immune system","volume":"9","author":"Ciabattini","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.immuni.2016.02.004","article-title":"The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons","volume":"44","author":"Carroll","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.10.047_b0135","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1002\/eji.201242372","article-title":"The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses","volume":"42","author":"Mori","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/icb.2013.92","article-title":"Immunity against a Chlamydia infection and disease may be determined by a balance of IL-17 signaling","volume":"92","author":"O\u2019Meara","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0145","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/IAI.00984-10","article-title":"Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during Chlamydia muridarum genital tract infection but is not required for macrophage influx or normal resolution of infection","volume":"79","author":"Scurlock","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.047_b0150","article-title":"Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses","volume":"1\u201311","author":"Christensen","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0155","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/ni.2552","article-title":"Plasticity of Th17 cells in Peyer\u2019s patches is responsible for the induction of T cell-dependent IgA responses","volume":"14","author":"Hirota","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0160","first-page":"181","article-title":"Studies on the mechanism of bile salt-induced liposomal membrane damage","volume":"28","author":"Schubert","year":"1983","journal-title":"Digestion"},{"key":"10.1016\/j.vaccine.2019.10.047_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02369","article-title":"The Chlamydia M278 major outer membrane peptide encapsulated in the poly(lactic acid)-poly(ethylene glycol) nanoparticulate self-adjuvanting delivery system protects mice against a Chlamydia muridarumgenital tract challenge by stimulating robust systemic","volume":"9","author":"Verma","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.10.047_b0175","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.clim.2012.12.005","article-title":"Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection","volume":"146","author":"Karlsson","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0180","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.047_b0185","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.vaccine.2013.11.100","article-title":"Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model","volume":"32","author":"Olsen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.047_b0190","article-title":"A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-\u03b3+ CMI responses protects against a genital infection in minipigs","volume":"1\u201311","author":"B\u00f8je","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00430","article-title":"Characterization of the antigen-specific CD4+ T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes","volume":"6","author":"Ciabattini","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0200","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.10.047_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00628","article-title":"Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with Chlamydia trachomatis","volume":"6","author":"Lorenzen","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13567-015-0241-9","article-title":"A review of the human vs. porcine female genital tract and associated immune system in the perspective of using minipigs as a model of human genital Chlamydia infection","volume":"46","author":"Lorenzen","year":"2015","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2019.10.047_b0215","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/iai.57.11.3484-3490.1989","article-title":"Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon","volume":"57","author":"Shemer-Avni","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.047_b0220","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.10.047_b0225","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ni.2871","article-title":"Toward a human vaccines project","volume":"15","author":"Koff","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2019.10.047_b0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/08982100902726820","article-title":"Liposome-based cationic adjuvant formulations (CAF): Past, present, and future","volume":"19","author":"Christensen","year":"2009","journal-title":"J Liposome Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:15:30Z","timestamp":1777536930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19314276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X19314276"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}